Cervical cancer represents the fourth most common and fatal form of cancer among women worldwide (1). More than 90% of cervical cancer cases arise as a consequence of a human papilloma virus (HPV) infection. Currently, 210 different HPV types have been officially recognized (2), and -based on their carcinogenic potential -have been classified either as low-risk HPV types, or as high-risk and potentially carcinogenic (3). Of the high-risk group, the five most common HPV types include HPV 16, 18, 45, 30, and 33, while types 16 and 18 alone, account for about 70% of all cervical cancer cases (4).In the early phase of cervical carcinogenesis, HPV initially infects the proliferating cells of the basal layer of the cervical stratified epithelium through abrasions of the mucosal epithelium. Following infection, the HPV genome remains in the form of nuclear extrachromosomal episome, and due to the repression of the viral E6 and E7 oncoprotein synthesis, the viral DNA replication occurs at very low levels (5). Following the gradual differentiation of the basal cells and their migration to the upper layers of the epithelium, an increased expression of E6 and E7 oncoproteins occurs, leading to inhibition of apoptosis, while the viral genome is replicated further. At this point, structural proteins and mature viral particles are produced, and the shed virus can then initiate a new infection. These 253 This article is freely accessible online.